A whole family of research compounds shares a single trick. GHRP-6, ipamorelin, MK-677 and their relatives don't deliver growth hormone from the outside — they nudge the body's own pituitary into releasing more of it. And because every one of these molecules is supplied for research use only, never for human or animal consumption, the useful question isn't "what does each one do to me." It's "what unites them as a class, and where do they part ways?" This article walks the growth hormone secretagogue class from the receptor up: the shared target, the peptide-versus-non-peptide split, the individual compounds researchers reach for, and what cell and animal models have actually recorded.
Thinking class-first pays off. Once you see that GHRP-6, ipamorelin and MK-677 all converge on one receptor, their differences — how well they survive the gut, how selective they are, how they read out in an assay — stop looking random and start looking like design choices.
What Defines the Growth Hormone Secretagogue Class
Here's the short answer before the chemistry: a secretagogue is anything that triggers secretion, and this class triggers the secretion of growth hormone (GH). What ties the members together isn't their shape but their target. Almost all of them act at the ghrelin / growth hormone secretagogue receptor, GHS-R1a — a G-protein-coupled receptor first cloned from mammalian pituitary tissue in 1996, and one that's genuinely distinct from the receptor used by growth hormone-releasing hormone (GHRH). That single shared target is the backbone of the whole category.
Picture two parallel roads to the same destination. One runs through GHS-R1a and its natural signal, ghrelin. The other runs through the GHRH receptor, home to compounds such as sermorelin, CJC-1295 and tesamorelin. Both roads end in more circulating growth hormone, but they're pharmacologically separate. This article stays on the first road — the ghrelin-mimetic branch. If you've read our explainer on another receptor-defined peptide class, the logic will feel familiar: define the family by the receptor it speaks to, then sort the members by chemistry.
Where the boundary sits
Membership has a catch. Simply binding the ghrelin receptor isn't enough to earn the "secretagogue" label. Ulimorelin, for instance, activates ghrelin receptors but is peripherally selective and produces little or no GH release, so it's not treated as a functional growth hormone secretagogue. In research terms, the class is defined by an effect — measurable GH-releasing activity — not merely by which receptor a molecule happens to touch.
Ghrelin, the Endogenous Ligand These Compounds Imitate
To understand a mimetic, start with what it mimics. Ghrelin is the body's own ligand for GHS-R1a: an acylated, 28-amino-acid peptide that links growth hormone release to broader metabolic and appetite signaling. When researchers call the synthetic secretagogues "ghrelin mimetics," they mean something specific. The synthetic molecules are, for the most part, structurally unlike ghrelin — some are short peptides, one flagship member isn't a peptide at all — yet they converge on the same receptor and reproduce part of its downstream signaling.
That word "part" matters. A mimetic isn't a copy. In research models, activation of GHS-R1a is associated with pulsatile GH release and downstream changes in insulin-like growth factor 1 (IGF-1), and different mimetics reproduce different slices of ghrelin's full signaling repertoire. Keeping the framing in observed-in-research terms — "in these models, the receptor did X" rather than "this compound will do X" — is the honest way to read the literature on a class that's still, in most respects, a research-stage story.
Peptide vs Non-Peptide Mimetics
The single most practical division in the class is chemical, and it drives almost everything about how a compound behaves in a study. On one side sit the peptide secretagogues: GHRP-1, GHRP-2 (pralmorelin), GHRP-6, hexarelin and ipamorelin. These are short amino-acid chains, and like most peptides they're fragile in the gut — oral bioavailability sits well under one percent, and their half-lives in study models are short, on the order of minutes. In practice, that means the peptide members get studied by non-oral, parenteral routes rather than by mouth.
On the other side sit the non-peptide mimetics, and here MK-677 (ibutamoren) is the anchor. As a small organic molecule rather than a peptide, MK-677 survives digestion far better: research has recorded greater than 60% oral bioavailability together with a long-lasting effect, which is exactly why it's described as the most orally active member of the class. Anamorelin, capromorelin and macimorelin round out the non-peptide side.